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Accepted 25 January 2016We designed a microﬂuidic chip for use with an evanescent ﬁeld optical sensor to conduct simultaneous mea-
surements for ABO and Rh(D) forward blood typing. The microﬂuidic chip was designed to include multiplexed
mixers for blood-reagentmixing and chambers for optical measurements. To achieve simple and rapidmixing in
themicroﬂuidic channels, holes containing freeze-dried reagents were employed asmixers. In addition, capillary
stop valve-basedmultiplexing of themeasurement chambers was used to effectively ﬁll the chamberswith sam-
ples without empty spaces or leaks. The ﬁve-channel microﬂuidic chip was designed and tested, including the
mixing holes and measurement chambers. A multi-channel waveguide-mode sensor was used for optical
measurement. Forward blood typing tests using human whole blood samples and anti-A, anti-B, anti-D, and
Rh control reagents were conducted on the microﬂuidic chip. Simultaneous measurements were successfully
performed using 40 μL of diluted blood samples, and ABO and Rh(D) blood types could be determined within
5 min.







Blood typing is important in clinical practice; in particular, ABO and
Rh(D) blood typing are commonly performed prior to blood transfu-
sions to prevent hemolysis caused by type mismatched. Manual test
methods, including those using a slide or a tube, and fully automated
test instruments are widely used at present [1]. In recent years novel
methods have been proposed to improve the sensitivity, usability,
or cost of conventional blood typing. These methods include optical
sensor-based [2–5], microﬂuidic device-based [6–8], and paper-based
[9–11] techniques. Methods that are suit for on-site use [5,6,9–11] are
candidates for point-of-care blood typing. Amethod needs to fully satis-
fy criteria, including sensitivity, usability, and low cost, to be used for
point-of-care blood typing. However, such a method has not been
developed.
Recently, we developed a method to rapidly and sensitively detect
hemagglutination [12]. Themethod, herein called the restrictive channel
method, uses a microﬂuidic channel paired with an evanescent ﬁeld op-
tical sensor. The channel functions as a spatial restraint against aggluti-
nated red blood cells (RBCs), resulting in signal differences between
agglutinated and non-agglutinated samples and thus allowing hemag-
glutination detection. In the previous report, we used a single-channelkuba, Ibaraki 305-8565, Japan.
jimaki@aist.go.jp (M. Fujimaki),
. This is an open access article undermicroﬂuidic chip and manual sample-reagent mixing before injection
into the channel. Although hemagglutination detection has been dem-
onstrated, multiplexing and automation of the measurements, which
are essential for point-of-care blood typing, have not yet been
established. The development of such a system holds promise for
improving conventional blood typing methods and merits further
investigation.
In this paper, we present a microﬂuidic chip for simultaneous ABO
and Rh(D) forward blood typing tests based on the restrictive channel
method. To enable simultaneous and semi-automated measurements
on microﬂuidic chips, a “mixer” for sample-reagentmixing and a “mea-
surement chamber” on the microﬂuidic chips were designed. A
waveguide-mode sensor, i.e., an evanescent ﬁeld optical sensor
equippedwith a slab optical waveguide, was used with themicroﬂuidic
chips. Five measurement channels were included on the microﬂuidic
chips to allow testing with anti-A, anti-B, anti-D, Rh control reagents,
and a reference blank. ABO and Rh(D) blood typing using our measure-
ment system were demonstrated and are described here. A droplet of
diluted blood (40 μL) was sufﬁcient for distinguishing blood types.
2. Material and methods
2.1. Materials
Reagents were used as received with no further puriﬁcation. Human
whole blood containing an anticoagulant (ethylenediaminetetraaceticthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Services Corporation (Memphis, TN, USA). Tubes containing fresh
blood samples were shipped by air and used within 2 weeks from the
day of collection. Hemolysis of samples was checked before use and
only non-hemolyzed samples were used. Blood types were conﬁrmed
by the supplier in advance. Blood-typing reagents for the ABO system
(monoclonal anti-A and anti-B, Neo Kokusai) were purchased from
Sysmex Corporation (Kobe, Japan). Blood-typing reagents for the
Rh(D) antigen (Ortho BioClone anti-D and Rh control) were purchased
from Ortho Clinical Diagnostics, Inc. (Raritan, NJ, USA) Phosphate-
buffered saline (PBS) was purchased fromWako Pure Chemical Indus-
tries, Ltd. (Osaka, Japan). Polydimethylsiloxane (PDMS) pre-polymer
and its curing reagent (SILPOT 184) were purchased from Dow Corning
Toray Co., Ltd. (Tokyo, Japan). Refractive indexmatching liquid for fused
silica (Fused Silica Matching Liquids 50,350) was purchased from
Cargille Laboratories Inc. (Cedar Grove, NJ, USA).Waveguide-mode sen-
sor chips were obtained from Shin-Etsu Chemical Co., Ltd. (Tokyo,
Japan).2.2. Waveguide-mode sensor
A multi-channel waveguide-mode sensor allowing up to 8 channels
for simultaneous measurements was used. A schematic diagram of the
measurement system is shown in Fig. 1(A). A collimated white light
was irradiated onto a waveguide-mode sensor chip at an incident
angle of 70.7°, and the reﬂected light was measured by a spectrometer.
The waveguide-mode sensor chip consisted of a surface silicon oxide
waveguide layer, an embedded silicon layer, and a silica substrate
[13]; the thicknesses of the layers were approximately 360 nm,
45nm, and0.725mm, respectively. The chip exhibited spectral dipmin-
ima at a wavelength of approximately 540 nm during blood sample
measurements. The chip was sensitive to RBC detection, as RBCs exhibit
a peak of absorbance at 540 nm [5]. The sensor measuredFig. 1. Schematic diagrams of hemagglutination detection using a microﬂuidic channel
and a waveguide-mode sensor. (A) Optical setup of a multi-channel waveguide-mode
sensor. Multi-optical paths are arrayed in the direction perpendicular to the paper
surface. (B) Typical curves representing changes in bottom reﬂectance at the spectral
dip minima (ΔR) against time measured using the waveguide-mode sensor. Insets show
the cross-sections of microﬂuidic channels ﬁlled with (i) agglutinated and (ii) non-
agglutinated blood samples.27 × 12 × 7.5 cm3 in external dimensions, a size amenable to portability
(see Supplementary Fig. S1).
2.3. Microﬂuidic structure preparation
The microﬂuidic structures were fabricated by replica molding of
PDMS using a silicon template. A 4 in. silicon wafer was processed by
a maskless lithography system (DL-1000; NanoSystem Solutions, Inc.,
Okinawa, Japan) and a reactive ion etching system (RIE-101iPH;
SAMCO Inc., Kyoto, Japan) to form the template. The PDMS pre-
polymer was mixed with the curing agent at a weight ratio of 10:1.
The mixture was poured onto the silicon template and degassed in a
vacuum for 60min. The PDMSvolumewas adjusted to reach a thickness
of approximately 3 mm. The template was then placed on a hot plate at
80 °C for 90 min. After removal from the template, the cured PDMS
microﬂuidic structures were punched to make inlets and outlets using
a biopsy punch with a diameter of 1.5 mm (BPP-15F; Kai Industries
Co., Ltd., Seki, Japan). The bonding between PDMS-glass surfaces or
PDMS-PDMS surfaces was performed using a plasma-bonding tech-
nique. The bonding surfaces were treated with a plasma cleaner (PDC-
32G; Harrick Plasma, Ithaca, NY, USA) for 20 s. The treated surfaces
were placed in contact immediately, and the assembly was placed on
a hot plate at 80 °C for 1 min. The assembled microﬂuidic chips were
placed in a dry chamber for 2 days before use to decrease hydrophilicity
resulting from the plasma treatment, since hydrophilic surfaces in the
microﬂuidic channels inhibit gapless sample ﬁlling.
2.4. Blood testing
Forward blood typing tests were conducted usingmicroﬂuidic chips
and a waveguide-mode sensor to detect hemagglutination. Human
whole blood was diluted with PBS to 10% of the RBC volume. The
microﬂuidic chips were placed on a prism of the waveguide-mode sen-
sor and the matching liquid ﬁlled the intermediate space. Tubing con-
taining the diluted blood was connected to the inlet; the other side of
the tubing was connected to a syringe pump. The blood samples were
introduced into the microﬂuidic chips using a syringe and mixed with
blood typing reagents. RBCs of blood samples that mixed with the cor-
responding blood typing reagents formed aggregates. After stopping
the ﬂow, reﬂected light spectra from the samples were measured by
thewaveguide-mode sensors, and changes in reﬂectance at the spectral
dip minima (ΔR) were analyzed.
A schematic diagramof typicalmeasurement data for the agglutinat-
ed and non-agglutinated blood samples is shown in Fig. 1(B). For the ag-
glutinated sample, aggregates of RBCs stayed motionless since their
gravitational sedimentation was restrained by themicroﬂuidic channel,
and thus ΔR was nearly zero. However, for the non-agglutinated sam-
ple, individual RBCs settled on the bottom surface of the microﬂuidic
channel. Since the waveguide-mode sensor is a surface-sensing tech-
nique, ΔR decreased over time owing to the settled individual RBCs.
Hemagglutination was detected by the presence or absence of a de-
crease in ΔR [12].
3. Results and discussion
3.1. Design and examination of the mixer
Microﬂuidic channels have low Reynolds numbers and are not con-
ducive to the mixing of liquids; accordingly, to facilitate mixing in
microﬂuidic channels, variousmicromixer devices have been developed
[14–16]. Although thesemixers are effective, it is not easy tomake them
compact; the lengths of the mixers range from millimeters to tens of
millimeters, and reservoirs for liquid reagents are needed. Our aim
was to design a simple and compact microﬂuidic system for use on
the sensor chips. Therefore, we explored various mixing techniques as
well as the use of freeze-dried reagents [17] encapsulated in “mixing
Fig. 2. Investigation of mixing holes to facilitate themixing of samples and reagents. (A) Schematic diagram of amixing hole. (B) Plots of changes in reﬂectance at the spectral dipminima
(ΔR) against timemeasured using blood samplesmixed at themixing holewith freeze-dried reagents. The sample used in thesemeasurements was type A blood. The datawere sampled
every 2 s. (C) Plots of ΔR against time measured using blood samples mixed with liquid reagents. The sample used in these measurements was the same blood as that used in (B).
Fig. 3. Design of measurement chambers. (A) Schematic diagram of the measurement
chambers. (B) Schematic diagram of capillary stop valve equipped with extra valves.
123H. Ashiba et al. / Sensing and Bio-Sensing Research 7 (2016) 121–126holes.” A schematic diagram of the mixing hole is shown in Fig. 2(A).
Themixing holes are through-holes between the upper and lower levels
of the microﬂuidic chip. When samples pass through the mixing holes
containing the freeze-dried reagents, the reagents are expected to dis-
solve into the sample. For forward blood typing, aggregates of RBCs
form in themixing holeswhen blood samples aremixedwith the corre-
sponding blood-typing reagents, and aggregates are then introduced
into measurement chambers. An important feature of the system is
that the mixing holes can produce aggregates of RBCs that are larger
than the height of the measuring chamber, since the height of the
mixing holes is larger than that of the chambers. As shown in
Fig. 1(B), the restrictive channel method detects hemagglutination
based on differences in ΔR that result from the difference in size be-
tween aggregates and individual RBCs. Larger aggregates effectively
suppress decreases in ΔR of the agglutinated samples. Thus, a distinct
difference between ΔR of agglutinated and non-agglutinated samples
is expected owing to the use of the mixing holes.
Themixing holes containing freeze-dried reagentswere tested using
a microﬂuidic channel and waveguide-mode sensor. The blood-typing
reagents were freeze-dried using FDU-1200 (AS ONE Corporation,
Osaka, Japan). Droplets of the reagents were put on a resin case and fro-
zen by incubation at−80 °C for 3 h, then freeze-dried at approximately
30 Pa for 3 h. The freeze-dried reagents retained their ability to aggluti-
nate RBCs (see Supplementary Fig. S2). Themicroﬂuidic channel used in
this test was a single straight channel with a width of 1.5 mm and a
height of 0.05 mm, which was identical to that used in a previous
study [12]. Through-holes with a diameter of 1.5 mm were made at
the ends of the channel using a biopsy punch and one hole was used
as themixing hole. Owing to deformation of the PDMS structures during
the punching process, the holes were not cylinders, but narrowed in the
middle. Approximately 0.04mg of freeze-dried reagentwas put into the
mixing hole. To connect the tubing, the upper PDMS structure was
bonded to the mixing hole with a 10-second plasma treatment and
5 min of hot plate heating at 36 °C. Milder bonding conditions were
employed compared to normal bonding conditions (described in
Section 2.3) to prevent damage to the encapsulated reagents. Diluted
type A blood was introduced into the channel and passed through
the mixing hole, and reﬂection spectra were measured with the
waveguide-mode sensor. Fig. 2(B) summarizes the ΔR values obtained
for the freeze-dried anti-A and anti-B reagents. Clear differences in
ΔR between the agglutinated (“Anti-A; freeze-dried”) and non-
agglutinated (“Anti-B; freeze-dried”) samples were observed, similar
to the typical curves shown in Fig. 1(B). For comparison, blood-typing
reagents without freeze drying were tested. For these measurements,
droplets of the reagents and the blood sample were gently mixed in ad-
vance using a pipette, and the mixture was then introduced into the
channel. The results are shown in Fig. 2(C). A similar signal was obtain-
ed for the measurements using the liquid reagents as compared tofreeze-dried reagents. These results conﬁrmed that the mixing holes
containing the freeze-dried reagents effectively mixed the blood sam-
ples and reagents.3.2. Design and examination of the measurement chambers
To conduct sample injections and blood typing in parallel, measure-
ment chambers equippedwith capillary stop valves [18] at their termini
were examined. A schematic diagram of the chambers is shown in
Fig. 3(A). According to our design, samples are injected into the cham-
bers in sequence, with samples stopping at the valves due to capillary
force, until all chambers are ﬁlled. Multichannel systems are typically
based on bifurcation-based multiplexing [6,19]. However, capillary
valve-based multiplexing can provide robust microﬂuidic systems that
allowﬂuid resistance variation,whereas bifurcation-basedmultiplexing
requires the precise control of ﬂuid resistance for sample ﬁlling. In addi-
tion, in the case of capillary valve-based multiplexing, the microﬂuidic
Fig. 4. Five-channel microﬂuidic chip for simultaneous blood typing measurements.
(A) Schematic diagram of the microﬂuidic chip design. (B) Photograph of the
microﬂuidic chip ﬁlled with human whole blood. Scale bar is 10 mm.
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therefore investigated a capillary valve-based multiplexing system.
The effects of the width of the capillary valve opening on function
were examined usingmicroﬂuidic chips containing three test chambers.
Capillary valveswith various openingwidthswere equipped at the ends
of the chambers. The diluted blood samples were introduced into the
chambers at various ﬂow rates controlled by a syringe pump. Stopping
was determined as “successful” if the samples were stopped at all
three chambers. The width, length, and height of the chambers were
1.5 mm, 7 mm, and 0.05 mm, respectively. Test results are summarized
in Table 1. The results indicate that an opening width not exceeding
20 μm is appropriate to stop the blood samples. A narrower opening
was considered to be unfavorable for smooth ﬂuid operation. Thus, we
employed 20 μm as the opening width and added three additional
valves at the terminus of each chamber, as shown in Fig. 3(B). These
valves effectively enhanced the stopping efﬁciency. In chambers
equippedwith this valve structure, only a few instances of sample over-
ﬂow were observed for more than a hundred sample injections.
3.3. Design of the ﬁve-channel microﬂuidic chip
A microﬂuidic chip for the simultaneous blood typing test was de-
signed and tested based on the same objectives as those for the mixing
holes and measurement chambers. A schematic diagram of the ﬁve-
channel-integrated microﬂuidic chip is shown in Fig. 4(A). The
microﬂuidic chip consisted of an upper microﬂuidic structure, a lower
microﬂuidic structure, and a waveguide-mode sensor chip. The upper
level contained an inlet and sample-dividing channel and the lower
level containedﬁvemeasurement chambers,withmixing holes situated
between the levels. Blood samples injected from the inlet were directed
to ﬁve channels, passed through the mixing holes, and then introduced
into themeasurement chambers. The freeze-dried anti-A, anti-B, anti-D,
and Rh control reagents were located in separate mixing holes at a
weight of approximately 0.04 mg per hole; the remaining mixing hole
was kept as a reference blank. The diameter and height of the mixing
holes were 1.5 mm and 3 mm, respectively. The shape of the chambers
was chosen to cover the spot size of incident light of the waveguide-
mode sensor. The height of the chamberwas set at 50 μm,which is pref-
erable for the restrictive channel method [12]. The three-strand capil-
lary stop valves with an opening width of 20 μm were located at the
ends of the chambers. The microﬂuidic chips were assembled using
plasma bonding under normal conditions (Section 2.3) and mild condi-
tions (Section 3.1).
Blood injection into themicroﬂuidic chipwas tested, without encap-
sulation of freeze-dried reagents, and the result is shown in Fig. 4(B).
Undiluted human whole blood was introduced into the chip by a sy-
ringe pumpwith a ﬂow rate of 15 μL/min. Blood was successfully divid-
ed into ﬁve channels, passed through the mixing holes, and introduced
into the measurement chambers without empty spaces or leaks.
3.4. Blood testing using the ﬁve-channel microﬂuidic chip
Fig. 5(A) summarizes the blood testing data obtained using our ﬁve-
channel microﬂuidic chip and type A+ blood and type A+ blood with
respect to time elapsed after blood samples reached the ﬁrstTable 1




20 40 60 80 100
1 ○ × × × ×
5 × ○ × × ×
10 ○ × × × ×
○: successful; ×: unsuccessful.measurement chamber. Blood samples (40 μL) were introduced into
the tubing connected to the chip inlet and injected into the chip with
a ﬂow rate of 15 μL/min. Approximately 30 s elapsed from the time
when samples passed the inlet to the time when they reached the ﬁrst
chamber. All of the chambers were ﬁlled in approximately 70 s (a series
of pictures illustrating the sample injection are shown in Supplementa-
ry Fig. S3), and then the syringe pump was stopped. As shown in
Fig. 5(A), a larger decrease in reﬂectance over time was observed for
the non-agglutinated samples (“Anti-B” and “Rh control”) than the ag-
glutinated samples (“Anti-A” and “Anti-D”). The reﬂectance at the pla-
teau for the “Blank” was considered the reﬂectance level of ideal non-
agglutinated samples. Fig. 5(B) shows the ΔR values calculated from
the measurements shown in Fig. 5(A). In this measurement, the de-
crease in ΔR of the non-agglutinated samples was larger than that of
the agglutinated samples, and thus hemagglutination was distinguish-
able. A picture of the microﬂuidic chip after the test is shown in
Fig. 5(C). Agglutination of RBCs was visually observed in a comparison
of the chamber containing anti-A reagent and that containing anti-B re-
agent. By contrast, the difference between the chamber containing anti-
D and Rh control was unclear based on visual observations. However,
ΔR measured by the sensor showed a difference caused by the hemag-
glutination reaction against the anti-D reagent, indicating that the re-
strictive channel method can detect smaller aggregates of RBCs than
visual inspection.
As revealed in Fig. 5(A), the determination of hemagglutination in all
measurement chambers was completed within 270 s; thus, blood type
was determined within 5 min, including sample delivery from the
inlet and mixing.
Fig. 5. Blood testing using the ﬁve-channelmicroﬂuidic chip. (A) Plots of reﬂectance at the
spectral dip minima (“Bottom reﬂectance”) against time. The origin of the abscissa
(“Elapsed time”) is the time point when blood samples reached the ﬁrst measurement
chamber. The data were sampled every 5 s. (B) Plots of changes in the bottom
reﬂectance (ΔR) against time. The origin of the abscissa (“Time”) is the time point when
the reﬂectance measurements of each chamber began, i.e., the start points for the plots
in Fig. 5(A) are shifted to 0 s. (C) Photograph of the microﬂuidic chip after blood testing.
Reagents encapsulated in each of the mixing holes are indicated. Scale bar is 10 mm. Al-
though the blood sample overﬂowed from the chambers, this occurred after theprocedure
when the tubing was removed from the chip. The stop valves worked efﬁciently during
the procedure, as shown in Supplementary Fig. S3.
Table 2
Summary of repeated measurements (N = 4) for type A+ blood samples.
Reagent Condition of RBCs ΔR at 180 s (%)
Average SE
Anti-A Agglutinated −12.5 3.3
Anti-B Non-agglutinated −23.2 0.5
Anti-D Agglutinated −22.5 2.4
Rh control Non-agglutinated −30.5 1.5
SE: standard error.
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Repeated measurements were conducted using the same blood
samples as those used to generate Fig. 5, and the ΔR values at 180 s
are summarized in Table 2. A similar trend as that shown in
Fig. 5(B) was obtained, i.e., the decrease in ΔR of the non-agglutinated
samples was larger than that of the agglutinated samples. A difference
between agglutinated and non-agglutinated samples was observed.
However, ΔR of the agglutinated samples showed a decrease, which
was not observed for the single-channel measurement shown in
Fig. 2(B). The |ΔR| of the agglutinated sample shown in Fig. 2(B) was
less than 1.5%. These results imply that mixing in the ﬁve-channel
chip was less effective than that in the single channel, although the de-
sign of the mixing hole was identical. We hypothesized that the differ-
ence in mixing efﬁciency reﬂects a difference in the volume of the
ﬂowed blood sample. Since the ﬂow of the sample stopped at the end
of the chamber, the volume of the sample that ﬂowed in each channel
of the ﬁve-channel chip was smaller than that of the single channel
test. Therefore, mixing in the ﬁve-channel chip was insufﬁcient and
less effective than that in the single channel test. To perform complete
mixing in the ﬁve-channel chip, an increased sample volume should
be passed through the measurement chamber. This can be implement-
ed by increasing the channel volume, i.e., via the addition of a reservoir
between themeasurement chamber and stop valve. Such amicroﬂuidic
chip should perform mixing as effectively as the single channel test.
Mixing performance can also be improved by revising the choice of
reagents. We used commercially available blood-typing reagents,
whichwere not intended to be freeze dried. Thus, some components in-
cluded in the reagents could disturb the ability to dissolve in blood sam-
ples. Moreover, improving the structure of the mixing holes may be
effective. A simple columnar structure was used for the mixing holes
in this study. By introducing a functionally-improved structure, such
as that used in micromixers to produce a vortex, the passive mixing of
reagents could be enhanced. Activemixing using external ﬁelds, includ-
ingmagnetic and electric ﬁelds, is also applicable. These approaches can
improve the performance of mixing, resulting in improved stability and
accuracy of hemagglutination detection.
3.6. Comparison among methods
Our microﬂuidic chip was capable of simultaneous measurements
for ABO and Rh(D) forward blood typing. To accommodate multi-
channel measurements using multiple reagents on microﬂuidic chan-
nels, the system can become complicated, requiring a number of
pumps, mechanical or electrical valves, and other microﬂuidic devices.
The complexity of the system arises from the need for a number of liq-
uids, including samples and reagents. In contrast, ourmicroﬂuidics chip
uses reagents in the form of freeze-dried powders and a single liquid
sample; accordingly, theﬂuidic system is simple and requires only a sin-
gle pump. Althoughwe used a syringe pump in this study, a diaphragm-
type micro-pumpwould also be applicable and would allow for a more
compact ﬂuidic system. By improving the usability of the inlet, a porta-
ble and fully automated measurement system could be developed. Al-
though our microﬂuidic chip was designed for point-of-care blood
typing, it can also be utilized for other assays by changing the encapsu-
lated reagents and applying surface modiﬁcations on the measurement
chambers, if needed. Such microﬂuidic chips are applicable to the
automation of other immunoassays and can decrease the volumes of
samples and reagents.
With respect to point-of-care blood typing, the leading candi-
dates among current blood typing methods are paper-based
techniques [9,11]. The measurement time for the developed microﬂuidic
chipwas less than 5min,which is compatible or faster than that of paper-
based systems (5–10 min). Our system is suitable for automation,
and thus the ease of operation is potentially compatible to that of the
paper-based assays. The cost of the test would be advantageous for the
126 H. Ashiba et al. / Sensing and Bio-Sensing Research 7 (2016) 121–126paper-based tests; however, our system provides additional beneﬁts,
such as its speed and automation. At the present stage, the sensitivity
and accuracy of the microﬂuidic chip have not been fully evaluated
owing to the limited number of available samples. Such tests will be con-
ducted in future work and these tests will include the improvements re-
lated to mixing performance described in Section 3.5.
From the viewpoint of practical operations, sample preparation is an
important step; our microﬂuidic chip requires the dilution of blood,
whereas some paper-based systems can be implemented with undilut-
ed blood. Thus, it is necessary to consider when and how collected
whole blood is diluted. Since the hematocrit of blood samples is usually
unknown, it is difﬁcult to prepare diluted samples containing a speciﬁc
percentage of RBCs. However, the appropriate dilution can be obtained
by using a tool for blood collection and a “6-fold dilution.” In a previous
study, the restrictive channel method was applicable for diluted blood
samples containing RBC volumes ranging from 5% to 10% [12]. The
microﬂuidic chip developed in this study operates in the same way;
thus, a 6-fold dilution of the collected blood can account for hematocrit
variation from 30% to 60%. The tool can be used to collect a speciﬁc
amount of patient blood and mix it with a speciﬁc amount of PBS. An
anticoagulant may be mixed along with PBS. Then, the 6-fold diluted
blood is introduced into the microﬂuidic chip. The development of
such a tool as well as a sensing instrument should be a priority for prac-
tical applications.4. Conclusion
A multi-channel microﬂuidic chip for simultaneous hemagglutina-
tion measurements was developed. To conduct parallel sample ﬁlling
and sample-reagent mixing using a simple ﬂuidic system, an appropri-
atemixer andmeasurement chamber were designed. Amixing hole en-
capsulated with freeze-dried reagents was employed as a mixer, which
allowed sample-reagent mixing by passing the samples through the
holes. The measurement chambers were equipped with capillary stop
valves at their ends to facilitate parallel sample ﬁlling. The capillary
valves, including four sequential valves with an opening width of
20 μm, showed almost 100% stopping efﬁciency for dozens of measure-
ments. Based on these results, a ﬁve-channel microﬂuidic chip was de-
signed and tested. The chip was tested using freeze-dried anti-A, anti-
B, anti-D, and Rh control reagents, which were encapsulated in the
mixing holes to conduct ABO and Rh(D) forward blood typing. Diluted
blood samples (40 μL) were injected into the chip and simultaneous
blood typing measurements were conducted in each of the chambers.
Hemagglutination was detected using the restrictive channel method,
and ABO and Rh(D) blood types were determinedwithin 5min. Further
improvements of the microﬂuidic chip can be implemented to increasethe stability and accuracy of hemagglutination detection, including the
introduction of a reservoir to increase mixing performance.
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